Fortress生物科技 FBIO 深 滬
等待開盤 08-26 09:30:00 美东时间
2.29
+0.020
+0.88%
華盛通- 最 高2.35
- 今 開2.28
- 成交量 51.58万股
- 最 低 2.24
- 昨 收 2.27
- 總市值 6813.85万
- 52周最高 2.36
- 市盈率 靜 --
- 換手率 1.73%
- 52周最低 1.325
- 委 比 -35.77%
- 總股本 2975.48万
- 歷史最高 190.50
- 量 比 1.12
- 振 幅 4.85%
- 歷史最低 1.325
- 每 手 1
- 風險率 0.38%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Fortress Biotech shares are trading higher after the company reported better-than-expected Q2 sales results.
Fortress Biotech shares are trading higher after the company reported better-th...
08-16 00:36
Fortress Biotech Q2 EPS $0.45 Beats $(0.36) Estimate, Sales $16.413M Beat $14.534M Estimate
Fortress Biotech (NASDAQ:FBIO) reported quarterly earnings of $0.45 per share which beat the analyst consensus estimate of $(0.36) by 225 percent. This is a 161.64 percent increase over losses of $(0.73) per share from
08-15 04:27
AstraZeneca’s Anselamimab Trial Shows Mixed Results
Fortress Biotech ( ($FBIO) ) has shared an update. On July 16, 2025, AstraZenec...
07-17 05:48
FibroBiologics Closes Third $5 Million Tranche of $25 Million Financing
FibroBiologics, a clinical-stage biotech company, has completed the third $5 million tranche of a $25 million Standby Equity Purchase Agreement (SEPA) with Yorkville Advisors Global, bringing total funding to $15 million. The company can seek an additional $10 million under the agreement, subject to approval. Proceeds will support research and development, including a Phase 1/2 diabetic foot ulcer clinical trial set to begin in late 2025. This co...
06-16 20:35
FibroBiologics Appoints Jason D. Davis, CPA, as Chief Financial Officer
FibroBiologics, a clinical-stage biotech company with 275+ patents, appointed Jason D. Davis, CPA, as Chief Financial Officer. With over 20 years of experience in corporate finance and capital markets, Davis will support the company’s growth as it advances its Phase 1/2 trial for diabetic foot ulcers. His expertise in leading IPOs and capital raisings will be crucial for FibroBiologics’ expansion of its fibroblast-based therapeutic platform.
06-09 12:30
Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics
Fortress Biotech's subsidiary, Checkpoint Therapeutics, has been acquired by Sun Pharma for $4.10 per share in cash, plus a contingent value right (CVR) up to $0.70 per share. Fortress will receive ~$28 million immediately, a 2.5% royalty on UNLOXCYT™ sales, and up to $4.8 million via CVR if certain conditions are met. UNLOXCYT™, the first FDA-approved PD-L1 blocker for advanced cutaneous squamous cell carcinoma, will be commercialized globally v...
05-30 14:47
Fortress Biotech Reports Q1 2025 Financial Highlights
Fortress Biotech Inc ( ($FBIO) ) has released its Q1 earnings. Here is a breakd...
05-20 11:57
Fortress Biotech Q1 EPS $(0.48) Beats $(0.49) Estimate, Sales $13.14M Beat $11.62M Estimate
Fortress Biotech (NASDAQ:FBIO) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(0.49) by 2.04 percent. This is a 53.85 percent increase over losses of $(1.04) per share from
05-16 04:31
Fortress Biotech Board Member Resigns for New Role
An announcement from Fortress Biotech ( ($FBIO) ) is now available. On April 15...
04-17 04:50
